ResearcherNorthwell HealthNo recent work listed

Shreya Prasad Goyal

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3937-9401; OpenAlex author ID A5048769950. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper

Papers 2

Neoadjuvant Therapy (NAT) in Localized Pancreatic Cancer: Should We Do It and What Should We Do? Co-author DOI 10.33696/signaling.2.037 ↗
Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged 65 years or older with advanced pancreatic cancer. Co-author DOI 10.1177/1756284820974912 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Muhammad Wasif Saif · 2 shared papers, 2020–2021 · strength 0.28
- Paper Neoadjuvant Therapy (NAT) in Localized Pancreatic Cancer: Should We Do It and What Should We Do? DOI 10.33696/signaling.2.037 ↗
- Paper Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged 65 years or older with advanced pancreatic c… DOI 10.1177/1756284820974912 ↗
Elliot Newman · 1 shared paper, 2021 · strength 0.16
- Paper Neoadjuvant Therapy (NAT) in Localized Pancreatic Cancer: Should We Do It and What Should We Do? DOI 10.33696/signaling.2.037 ↗
Nausheen Hakim · 1 shared paper, 2020 · strength 0.12
- Paper Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged 65 years or older with advanced pancreatic c… DOI 10.1177/1756284820974912 ↗
Jeffrey Chi · 1 shared paper, 2020 · strength 0.12
- Paper Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged 65 years or older with advanced pancreatic c… DOI 10.1177/1756284820974912 ↗
Hasan Rehman · 1 shared paper, 2020 · strength 0.12
- Paper Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged 65 years or older with advanced pancreatic c… DOI 10.1177/1756284820974912 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.